109182
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于壳聚糖的抗癌药物载体用于肺癌治疗的前景与挑战：综述
Authors Liu Y , Yang B, Chen H, Liao Y, Zhang S, Yang J , Chen W , Liu H
Received 19 July 2025
Accepted for publication 4 October 2025
Published 25 October 2025 Volume 2025:19 Pages 9581—9599
DOI https://doi.org/10.2147/DDDT.S544567
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Muzammal Hussain
Yan Liu,1,* Baolian Yang,2,* Hao Chen,1 Yumei Liao,3 Shiyu Zhang,3 Jianqiong Yang,4 Weiliang Chen,1 Hai Liu1
1Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, College of Pharmacy, Gannan Medical University, Ganzhou, 341000, People’s Republic of China; 2Department of Manufacturing Laboratory, Ganzhou Hospital of Traditional Chinese Medicine, Ganzhou, 341000, People’s Republic of China; 3Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, 341000, People’s Republic of China; 4Ganzhou Key Laboratory of Antitumor Effects of Natural Products, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weiliang Chen; Hai Liu, Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, College of Pharmacy, Gannan Medical University, Ganzhou, 341000, People’s Republic of China, Email liuhaiuser@163.com
Abstract: Lung cancer remains one of the leading causes of cancer-related mortality and morbidity worldwide. Despite significant advancements in diagnostic techniques and therapeutic modalities such as surgery, chemotherapy, and radiotherapy, there is an urgent need for innovative therapeutic approaches due to severe adverse reactions, escalating multidrug resistance, an increased risk of tumor recurrence, and the complexity of the tumor microenvironment (TME). Nanotechnology-based drug delivery systems have emerged as a novel strategy for lung cancer treatment by enhancing drug targeting, reducing toxic side effects, and improving bioavailability. Chitosan (CS) has emerged as a promising candidate material for anticancer drug delivery carriers due to its unique physicochemical properties, biocompatibility, and biodegradability. This review summarizes recent research progress on CS nanocarriers for lung cancer treatment and elucidates their challenges and future prospects for clinical transformation.
Keywords: chitosan, lung cancer, nanocarriers, drug delivery systems, phototherapy
1Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, College of Pharmacy, Gannan Medical University, Ganzhou, 341000, People’s Republic of China; 2Department of Manufacturing Laboratory, Ganzhou Hospital of Traditional Chinese Medicine, Ganzhou, 341000, People’s Republic of China; 3Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, 341000, People’s Republic of China; 4Ganzhou Key Laboratory of Antitumor Effects of Natural Products, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weiliang Chen; Hai Liu, Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, College of Pharmacy, Gannan Medical University, Ganzhou, 341000, People’s Republic of China, Email liuhaiuser@163.com
Abstract: Lung cancer remains one of the leading causes of cancer-related mortality and morbidity worldwide. Despite significant advancements in diagnostic techniques and therapeutic modalities such as surgery, chemotherapy, and radiotherapy, there is an urgent need for innovative therapeutic approaches due to severe adverse reactions, escalating multidrug resistance, an increased risk of tumor recurrence, and the complexity of the tumor microenvironment (TME). Nanotechnology-based drug delivery systems have emerged as a novel strategy for lung cancer treatment by enhancing drug targeting, reducing toxic side effects, and improving bioavailability. Chitosan (CS) has emerged as a promising candidate material for anticancer drug delivery carriers due to its unique physicochemical properties, biocompatibility, and biodegradability. This review summarizes recent research progress on CS nanocarriers for lung cancer treatment and elucidates their challenges and future prospects for clinical transformation.
Keywords: chitosan, lung cancer, nanocarriers, drug delivery systems, phototherapy